All application pathways below describe the use of (bromomethyl)cyclopropane as a pharma-grade N-alkylating intermediate in the synthesis of morphinan-derived active pharmaceutical ingredients. The substance is not individually compressed, granulated, or lyophilized into final dosage forms; its residual control, stoichiometric behavior, and solvent selection determine whether the resulting API is suitable for oral solid, transmucosal, or injectable presentation. The downstream routes selected are limited to documented morphinan structures where the 17-cyclopropylmethyl substituent is pharmacologically required or introduced via the corresponding secondary amine.

During commercial manufacture of naltrexone hydrochloride destined for 25 mg and 50 mg oral film-coated tablets, the cyclopropylmethyl substituent is introduced onto noroxymorphone free base by N-alkylation with (bromomethyl)cyclopropane in glass-lined or Hastelloy C-22 reactors. The alkylating agent is typically charged at 1.05–1.25 molar equivalents relative to noroxymorphone free base, with sodium bicarbonate at 1.20–1.50 molar equivalents as acid scavenger in anhydrous N,N-dimethylformamide; the batch is held at 60–75 °C for 12–18 h under a continuous nitrogen sweep, and conversion is monitored by HPLC with an in-process limit of noroxymorphone ≤ 2.0 area%. The reaction mass is quenched into cold water, extracted with ethyl acetate, washed with dilute sodium chloride solution, concentrated under reduced pressure, and the resulting naltrexone base is crystallized from acetone/water before conversion to the hydrochloride salt with hydrogen chloride in 2-propanol. The dried API is sieved to D90 ≤ 180 µm and blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate using dry granulation or direct compression; compressed tablets are film-coated to target hardness 8–14 kP and tested for disintegration per USP <701>. Release is controlled against USP 43–NF 38 Naltrexone Hydrochloride monograph, 21 CFR 211, ICH Q7, residual solvent limits under ICH Q3C, mutagenic impurity control under ICH M7, and residual bromide by ion chromatography; related substances are quantified by HPLC with specified unspecified impurity limits ≤ 0.10%. The terminal product type is oral film-coated tablet, with granulation conducted only as an intermediate step rather than a marketed granule or capsule presentation.

Why Does Injectable-Grade Naltrexone Require Tighter Residual Bromide and Solvent Controls Than Tablet-Grade Material?

For extended-release intramuscular injection, naltrexone is processed as the free base rather than the hydrochloride salt because the solubility and release profile in poly(D,L-lactide-co-glycolide) 75:25 microspheres must be controlled over a multi-week depot period. In this injectable pathway, the N-alkylation step is shifted to a less volatile solvent system: bromomethylcyclopropane is charged at 1.10–1.30 molar equivalents with potassium carbonate at 1.60–2.00 molar equivalents in dimethyl sulfoxide, maintained at 50–65 °C for 16–24 h. The lower temperature and higher base charge reduce the formation of the quaternary ammonium by-product that is more difficult to purge from the free base. After water quench and phase separation, the naltrexone base is reslurried in water/ethanol and dried to ≤ 0.5% water; residual dimethyl sulfoxide is controlled to ≤ 0.5% under ICH Q3C Class 3, and residual inorganic bromide is monitored by ion chromatography with a product-specific release limit derived from terminal dose safety. The purified base is micronized and incorporated into 75:25 PLGA microspheres by a solvent extraction/evaporation process; the lyophilized microsphere powder is terminally suspended in an aqueous diluent immediately before intramuscular administration at a label strength of 380 mg naltrexone per vial. Compliance includes ICH Q7, 21 CFR 210/211, the USP 43–NF 38 Naltrexone for Extended-Release Injectable Suspension monograph, USP <788> particulate matter, USP <85> bacterial endotoxins, and ICH M7 for alkyl bromide control. Published data for the exact release limits of this specific microsphere configuration is limited; batch controls are therefore established through process validation rather than compendial substitution. The terminal product type is injectable suspension for intramuscular depot.

The 17-cyclopropylmethyl substituent in buprenorphine hydrochloride is installed by treating a demethylated oripavine-derived morphinan intermediate with bromomethylcyclopropane in a polar aprotic medium under inert atmosphere. The alkylating agent is added at 1.10–1.40 molar equivalents relative to the secondary amine intermediate, with potassium carbonate at 1.50–2.00 molar equivalents in acetonitrile or a mixed acetonitrile/DMF system at 50–65 °C for 12–20 h. Unlike the naltrexone route, the process uses staged addition of the alkyl bromide to limit the exotherm and to keep residual unreacted bromomethylcyclopropane below the threshold that would otherwise convert to volatile by-products during downstream salt formation or lyophilization. The resulting buprenorphine base is crystallized from 2-propanol/water, then converted to the hydrochloride salt and micronized to a particle size distribution suitable for sublingual absorption. Terminal dosage forms include 2 mg and 8 mg sublingual tablets and oral lyophilisates; direct compression and freeze-dried unit-dose formats are both used, with dissolution testing per USP <711> and Ph. Eur. 2.9.3. Regulatory controls include ICH Q7, ICH Q3C, ICH M7, the current USP Buprenorphine Hydrochloride monograph, Ph. Eur. Buprenorphine Hydrochloride monograph, and 21 CFR 1300 controlled-substance security requirements. This sublingual tablet segment is differentiated by the need to control residual solvent and alkyl bromide at low levels because the dosage form is held in the oral cavity, and because swallowed portions of the dose undergo extensive first-pass metabolism, making dissolution and transmucosal particle size critical parameters rather than optional release checks.

Nalmefene Hydrochloride and the 6-Methylene Route: Volatility Transfer in Granulation

In the production of nalmefene hydrochloride for 18 mg film-coated tablets, the cyclopropylmethyl group is introduced through the naltrexone intermediate before installation of the 6-methylene group; bromomethylcyclopropane is therefore consumed in the same N-alkylation step described for naltrexone, but its residual profile must survive additional downstream chemistry. The alkylation charge is typically 1.05–1.35 molar equivalents with N,N-diisopropylethylamine at 1.60–2.20 molar equivalents in anhydrous N,N-dimethylformamide at 60–75 °C for 10–16 h. After work-up and 6-methylene formation, the crude nalmefene base is isolated as the hydrochloride salt from ethanol/ethyl acetate; residual bromide is controlled before salt formation because bromide can influence the dissolution stability of the finished film-coated tablet. The API is wet-milled to D50 ≤ 30 µm, then dry granulated with mannitol, crospovidone, and sodium stearyl fumarate before compression to 18 mg. This terminal dosage form is approved for reduction of alcohol consumption in some jurisdictions and is controlled under EMA product monographs, ICH Q7, ICH Q3C, ICH M7, 21 CFR 211 for sites supplying the US market, and USP <711> dissolution. The granulation route differs from naltrexone tablet manufacture in that the API is incorporated only after milling, because the 6-methylene moiety increases mechanical shear sensitivity during roller compaction. The terminal product type is film-coated oral tablet; no marketed capsule or granule presentation is derived from this exact morphinan configuration.

Sublingual and Injectable Buprenorphine Hydrochloride: Residual Solvent Partitioning Across Aqueous and Lipophilic Formulations

Injectable-grade buprenorphine hydrochloride is manufactured to meet bacterial endotoxin and particulate standards not applied to solid oral dosage forms. The synthetic route may be identical to the sublingual API route, but the molar excess of bromomethylcyclopropane is held at the lower end of the commercial range, 1.05–1.20 molar equivalents, to reduce unreacted alkylating agent and associated lipophilic by-products that partition into the free base and are difficult to remove during terminal sterile formulation. The N-alkylation is conducted in acetonitrile/dimethyl sulfoxide with 1.50–1.80 molar equivalents of potassium carbonate at 55–65 °C for 14–18 h; after phase separation and salt formation, the API is recrystallized from aqueous ethanol and dried to ≤ 0.3% water. Aqueous solution for injection is prepared by dissolving the hydrochloride salt in water for injection, adjusting the pH to 3.0–3.5 with dilute hydrochloric acid, and terminal sterile filtration through a 0.22 µm PVDF filter; the filtrate is filled aseptically into 1 mL ampoules at 0.3 mg/mL. Extended-release subcutaneous injection formats require additional control of residual solvents and alkyl bromide because the depot matrix can retain lipophilic impurities for weeks. Compliance includes USP <1>, USP <85>, USP <788>, 21 CFR 210/211, 21 CFR 1300, ICH Q7, ICH Q3C, and ICH M7. This segment is distinct from sublingual tablets because the API is not micronized for transmucosal retention but is dissolved and sterile-filtered, which shifts the control burden from particle size to bioburden, endotoxin, and filter compatibility. The terminal product type is aqueous injectable solution or extended-release subcutaneous injection.

When Bromomethylcyclopropane Is Used in Continuous-Flow Alkylation of Morphinan Cores at Scale

Continuous-flow N-alkylation with bromomethylcyclopropane is employed in engineering batches for morphinan-derived intermediates where the alkyl bromide exhibits a pronounced exotherm and a low flash point that make batch addition in large reactors difficult to control. The feed stream is configured with a molar ratio of 1.10–1.30 bromomethylcyclopropane to the morphinan amine, with an organic base in a homogeneous DMF/acetonitrile mixture; residence time is 60–120 min in a silicon carbide or glass microreactor maintained at 70–80 °C and 2–5 bar back pressure to suppress vapor formation. In-line process analytical technology, typically attenuated total reflectance FTIR or automated HPLC sampling, tracks disappearance of the secondary amine and generation of the quaternary ammonium impurity; when the quaternary impurity exceeds the pre-set control limit, the feed ratio is automatically reduced. The reactor outlet is quenched in-line into aqueous acid, and the biphasic stream enters a continuous liquid-liquid separator; the organic phase is concentrated and sent to a continuous crystallizer to isolate the free base or hydrochloride salt. Published data for this exact flow configuration is limited, and engineering batches are qualified under ICH Q7 rather than a compendial flow monograph; residual alkylating agent is controlled under ICH M7, residual solvents under ICH Q3C, and terminal dosage forms may include oral tablets, granules, capsules, or sterile injectables after appropriate downstream crystallization and salt formation. This route is specifically relevant when the target API is a 17-cyclopropylmethyl morphinan with high potency and low dose, where batch-to-batch variability in residual bromide or related substances must be minimized.